Comprehensive prognostic scoring systems could improve the prognosis of adult acute myeloid leukemia patients.
Acute myeloid leukemia (AML)
Comprehensive prognostic scoring system (CPSS)
Gene mutations
Next-generation sequencing (NGS)
Prognosis
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
18
04
2019
accepted:
06
08
2019
revised:
06
08
2019
pubmed:
24
8
2019
medline:
18
3
2020
entrez:
24
8
2019
Statut:
ppublish
Résumé
Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by a dismal outcome. To enable better outcomes, it is necessary to develop individual therapies based on risk stratification. In the present study, we established two new comprehensive prognostic scoring systems (CPSS) for overall survival (OS) and relapse-free survival (RFS) using the Cox proportional hazards regression, CPSS integrated and weighted age, AML type, lactic dehydrogenase (LDH), ECOG score, cytogenetics, and gene mutations. We divided patients into three risk groups-low-, intermediate-, and high-risk-with 1-year OS rates of 100.0%, 82.9%, and 38.2%, respectively (p < 0.0001), and patients undergoing complete remission (CR) were also separated into low-risk, intermediate-risk, and high-risk groups, with 1-year RFS rates of 87.7%, 58.4%, and 30.2%, respectively (p < 0.0001). We conclude that CPSS that integrate clinical characteristics, cytogenetic abnormalities, and gene mutations may improve the stratification of AML patients.
Identifiants
pubmed: 31440963
doi: 10.1007/s12185-019-02721-y
pii: 10.1007/s12185-019-02721-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
575-583Subventions
Organisme : National Natural Science Foundation of China
ID : 81570116
Organisme : National Natural Science Foundation of China
ID : 81873434
Références
Haematologica. 2003 Apr;88(4):429-37
pubmed: 12681970
Leuk Lymphoma. 2011 Dec;52(12):2329-35
pubmed: 21745171
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
N Engl J Med. 2018 Mar 29;378(13):1189-1199
pubmed: 29601269
Mol Cancer Res. 2013 Aug;11(8):815-27
pubmed: 23645565
Br J Haematol. 2009 Jun;145(5):598-605
pubmed: 19344426
Blood. 2010 Aug 12;116(6):971-8
pubmed: 20442365
Leukemia. 2014 May;28(5):1132-4
pubmed: 24226631
Leukemia. 2011 Mar;25(3):420-8
pubmed: 21135859
Med Oncol. 2013 Mar;30(1):394
pubmed: 23275122
Lancet. 2018 Aug 18;392(10147):593-606
pubmed: 30078459
Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S62-S74
pubmed: 28760304
Stem Cell Investig. 2017 Feb 09;4:6
pubmed: 28217708
J Clin Oncol. 2017 Mar 20;35(9):934-946
pubmed: 28297624
Haematologica. 2018 Feb;103(2):256-265
pubmed: 29242299
Leukemia. 2014 Jul;28(7):1449-58
pubmed: 24402164
J Clin Oncol. 2015 Nov 1;33(31):3641-9
pubmed: 26304885
Oncotarget. 2017 Dec 22;9(4):4961-4968
pubmed: 29435155
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Blood Cancer J. 2018 Aug 7;8(8):76
pubmed: 30087318
PLoS One. 2016 Jan 15;11(1):e0146614
pubmed: 26771376
Haematologica. 2008 Dec;93(12):1806-13
pubmed: 18838471
J Clin Oncol. 2014 May 20;32(15):1586-94
pubmed: 24711548
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
J Clin Med. 2015 Mar 12;4(3):460-78
pubmed: 26239249
Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):163-71
pubmed: 24461514
Hematol Oncol Stem Cell Ther. 2017 Mar;10(1):1-7
pubmed: 27613372
J Natl Compr Canc Netw. 2017 Jul;15(7):926-957
pubmed: 28687581
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
J Clin Oncol. 2008 Oct 10;26(29):4791-7
pubmed: 18695255
Am J Manag Care. 2018 Aug;24(16 Suppl):S347-S355
pubmed: 30132678
Cancer Med. 2017 Feb;6(2):349-360
pubmed: 28070990
Trends Biochem Sci. 2012 May;37(5):179-88
pubmed: 22480731
Am Soc Clin Oncol Educ Book. 2018 May 23;38:555-573
pubmed: 30231330
J Chin Med Assoc. 2006 Nov;69(11):534-7
pubmed: 17116616